Antipsychotic drug toxicology in children (Q37852719)

24 August 2017

1 reference

title

Antipsychotic drug toxicology in children (English)

1 reference

24 August 2017

2

Antonio Clavenna

1 reference

24 August 2017

Silvio Caccia

1

1 reference

24 August 2017

Maurizio Bonati

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

Expert Opinion on Drug Metabolism & Toxicology

24 August 2017

language of work

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

591-608

1 reference

National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Treatment of early-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Current schizophrenia drugs: efficacy and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Review of antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Optimizing pediatric dosing: a developmental pharmacologic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Biotransformation of Post-Clozapine Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Metabolic drug interactions with newer antipsychotics: a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Therapeutic drug monitoring in pediatrics: how do children differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Pharmacogenetics of classical and new antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

A review of developmental aspects of cytochrome P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Hematological adverse events in clozapine-treated children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Chlorpromazine disposition in relation to age in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Pharmacokinetics of haloperidol: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Antipsychotic drugs and QT prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Pharmacokinetics of pimozide in adults and children with Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Plasma pimozide profiles in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Sulpiride: an antipsychotic with selective dopaminergic antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

A pharmacokinetic study of trifluoperazine in two ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Plasma amisulpride levels in schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Is there a role for clozapine in the treatment of children and adolescents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Atypical antipsychotic metabolism and excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Olanzapine: in adolescents with schizophrenia or bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Large intraindividual variability of olanzapine serum concentrations in adolescent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Pediatric uptake of a newly available antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Ethical issues in psychopharmacology of children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

Amisulpride: a review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562198

10.1517/17425255.2011.562198

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference